Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alcohol spray Clear all
Recruiting Phase 2 Interventional

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT06927999
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Placebo, 0.5 mg epinephrine, 1 mg epinephrine
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glenview, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

NCT06262347
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related, Substance Use, Drug Abuse, Drug Abuse in Pregnancy, Drug Addiction
Interventions
Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME), Control
Behavioral
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Jacksonville, Florida • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 20, 2026, 5:33 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Anxiety Disorder
Interventions
Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Oxytocin Treatment of Alcohol Withdrawal

NCT01212185
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
intranasal oxytocin spray, intranasal spray without oxytocin
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin Treatment of Alcohol Dependence

NCT02251912
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 20, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

NCT01873131
View directory record Official record
Conditions
Hemangioma
Interventions
topical timolol maleate, Pulsed dye laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Months
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751631
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 20, 2026, 5:33 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

NCT06865170
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions
25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

NCT04523922
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

NCT00296530
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

NCT00699556
View directory record Official record
Conditions
Alcohol Drinking
Interventions
21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02116309
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Rectal Indomethacin, Epinephrine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

NCT00296491
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
104
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
View directory record Official record
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

NCT02469259
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcoholism
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 20, 2026, 5:33 PM EDT
Not listed Phase 3 Interventional

Effect of Symbicort on Sleep Quality in Patients With Emphysema

NCT01602523
View directory record Official record
Conditions
Emphysema, Poor Sleep Quality
Interventions
Budesonide/formoterol, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

Blinded Dry Mouth Spray Crossover Study

NCT04608773
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer, Xerostomia Following Radiotherapy
Interventions
Remineralizing Extreme Dry Mouth Spray with Xylitol, Alcohol-Free Moisturizing Dry Mouth Spray
Other · Device
Lead sponsor
Jonas Johnson
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 20, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Alcohol and Cigarette Craving During Oxytocin Treatment

NCT04071119
View directory record Official record
Conditions
Alcohol Use Disorder, Smoking
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 20, 2026, 5:33 PM EDT